Meetings

Washington, D.C. – May 1, 2025 – New data highlights juxtaposing trends in serious obesity-related cardiovascular events. A recent study details the obesity paradox in patients with critical limb ischemia (CLI), demonstrating lower mortality in patients with obesity by 50% compared to non-obese patients.

Washington, D.C. – May 1, 2025 – New findings from multiple studies demonstrate that glucagon-like peptide-1 receptor agonists (GLP-1RAs), a class of medications used to treat type 2 diabetes, play a significant role in improving cardiovascular outcomes like heart failure (HF), acute myocardial infarction (AMI), peripheral artery disease (PAD), and ST-elevation myocardial infarction (STEMI).

Washington, D.C. – May 1, 2025 – New findings from FAVOR III China Trial, presented today as late-breaking science at the Society for Cardiovascular Angiography & Interventions (SCAI) 2025 Scientific Sessions, showed that machine learning-based approach identify top 10 prognostic factors for predicting 2-year major adverse cardiovascular events (MACE) after Quantitative Flow Ratio (QFR)-guided Percutaneous Coronary Intervention (PCI) and therefore may improve individual risk prediction.

Washington, D.C. – MAY 1, 2025 – In one of the largest studies of early cardiogenic shock (CS) patients, where blood flow is still functioning to vital organs, researchers demonstrated that 26% experienced worse outcomes, including care escalation, CS deterioration, or in-hospital mortality.

Washington, D.C. – MAY 1, 2025 – The first study evaluating Medicare patients undergoing percutaneous coronary intervention (PCI) in ambulatory surgery centers (ASCs) demonstrated good safety outcomes, such as mortality and adverse event rates at 30 days, compared to outpatient hospital departments, but were less likely to use certain technologies.

Washington, D.C. – MAY 1, 2025 – In patients undergoing chronic total occlusion (CTO) percutaneous coronary intervention (PCI), stenting demonstrated improved long-term survival and fewer cardiac arrests at one year.

Washington, D.C. – May 1, 2025 – New data finds women 8% more likely to experience major complications after transcatheter aortic valve implantation (TAVI) and 50% more likely after left atrial appendage occlusion (LAAO) device placement.

Washington, D.C. – MAY 1, 2025 – Findings from the Transfusion Requirements in Transcatheter Aortic Valve Implantation (TRITAVI) registry demonstrate that single antiplatelet therapy (SAPT) after transcatheter aortic valve replacement (TAVR) is associated with a significantly lower incidence of six-month mortality and major bleeding risk compared to dual antiplatelet therapy (DAPT).

Washington, D.C. – May 1, 2025 – Analyses from the (Ergonomics in the Cardiac Catheterization Laboratory (ERGO-CATH) study show the traditional approach using a lead apron causes 43% of interventional cardiologists to experience discomfort, building on existing consensus of the significant occupational health risks that exist in the catheterization (cath) lab.